Netherlands· NL-e82dfcb31242
Akeega 100 mg/500 mg filmomhulde tabletten
A antineoplastic agents product containing abirateronacetaat + niraparibtosilaat 1-water, registered in Netherlands by Janssen-Cilag International NV. The same ATC class is registered in 6 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Abirateronacetaat + niraparibtosilaat 1-water is registered in 6 of 19 countries.
Countries holding a registration under ATC L01 (antineoplastic agents), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 3 of them publish a price we can compare per daily dose
Abirateronacetaat + niraparibtosilaat 1-water · ATC L01
6 / 19 countries
- Canada
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ABIRATERONACETAAT + NIRAPARIBTOSILAAT 1-WATER
- Manufacturer
- Janssen-Cilag International NV
- Country
- Netherlands (NL)
- ATC code
- L01
- ATC class
- ANTINEOPLASTIC AGENTS
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/23/1722
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Abirateronacetaat + niraparibtosilaat 1-water in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAKEEGAJanssen Biotech, Inc.
- SwitzerlandAkeega
- CzechiaAKEEGAJanssen-Cilag International N.V., Beerse
- SpainAKEEGA 100 MG/500 MG COMPRIMIDOS RECUBIERTOS CON PELICULAJanssen-Cilag International N.V
- FinlandAkeegaJanssen-Cilag International NV
- SwedenAkeega 100 mg/500 mg Filmdragerad tablettJanssen-Cilag International NV
- CanadaAKEEGAJANSSEN INC
- United KingdomAkeega 100mg/500mg tabletsJanssen-Cilag Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Akeega
- Liechtenstein · Akeega
- Norway · Akeega
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a7470001-babc-41b9-92e6-c604456d5b3a GET /v1/drugs/a7470001-babc-41b9-92e6-c604456d5b3a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Antineoplastic Agents",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130002",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSPOVIDON (E 1202)",
"GLYCEROL MONOCAPRYLOCAPRAAT, TYPE I",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ROOD (E 172)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMLAURILSULFAAT",
"POLYVINYLALCOHOL (E 1203)",
"SILICIUMDIOXIDE (E 551)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"ABIRATERONACETAAT",
"NIRAPARIBTOSILAAT 1-WATER"
],
"leaflet_url": null,
"authorised_at": "2023/04/19",
"procedure_number": "EMEA/H/C/005932",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/23/1722",
"additional_monitoring": "N"
}See everything about abirateronacetaat + niraparibtosilaat 1-water.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.